Radiation Therapy Most Common Treatment for Prostate Cancer

This article originally appeared here.
Share this content:
Radiation Therapy Most Common Treatment for Prostate Cancer
Radiation Therapy Most Common Treatment for Prostate Cancer

FRIDAY, Feb. 20, 2015 (HealthDay News) -- New research suggests that a wait-and-watch approach for prostate cancer isn't being used often enough, and that more men are being treated than may be necessary. The study appears online Feb. 19 in JAMA Oncology.

Additionally, the researchers expressed concern about the numbers of men being treated with radiation therapy, regardless of their tumor specifics. "Too many men are being treated for prostate cancer, and too many are being treated with radiation therapy," study lead author Karim Chamie, M.D., an assistant professor of urology at the University of California in Los Angeles, told HealthDay.

In the new study, the researchers aimed to figure out why many men don't choose the wait-and-watch option. The investigators tracked 37,621 men in the United States who were diagnosed with prostate cancer between 2004 and 2007. The researchers followed the men, who were all at least 65 when diagnosed, through 2009. Only 10 percent of those diagnosed chose to forgo treatment, at least temporarily, the investigators found. Almost 58 percent of the men chose radiation therapy, while 19 percent had their prostate removed.

Sandip Prasad, M.D., an assistant professor of urology at the Medical University of South Carolina in Charleston, who co-wrote a commentary in the same issue of the journal, didn't go as far as to say that radiation is overused. Still, he told HealthDay: "We believe treatment -- radiation or surgery -- shouldn't be 90 percent of what's being done."

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »